U.S. pharmaceutical company Moderna announced on the 26th (local time) that it will begin developing an “in vivo CAR-T” ...
Please provide your email address to receive an email when new articles are posted on . The first four patients dosed achieved early MRD-negative bone marrow. No grade 3 or higher hematologic toxicity ...
Therorna to Showcase Clinical-Ready Circular RNA in vivo CAR-T and CircRNA Pipeline at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting TI-0032 first-in-human study initiated; ...
This review article highlights the transformative potential of in vivo CAR T cell therapy in addressing the limitations of traditional CAR T cell production. This innovative approach could ...
CAR-T Therapy continues to evolve rapidly, mRNA encoding CAR constructs directly to T cells in the bloodstream, potentially enabling CAR T cell production in the body without the need to isolate and ...
Enabling patients to generate CAR T-cells internally could cut kidney cancer therapy costs, explained Dr. Wayne Marasco of Dana-Farber Cancer Institute. In vivo CAR T-cell therapy could drastically ...
Image Caption: The basic structure of five generations of CAR T cells. Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on ...
After recalibrating its production strategy in the late 2010s to better meet the realities of the CAR-T market, Gilead Sciences’ Kite Pharma is preparing to hit the ground running with the potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results